Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | ITGAL | P20701 | 1/20 | 0.35 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757859 | 0.78 | — | — | |
| SCHEMBL971330 | 0.69 | MAOA (0.70) | MAOAMAOBTSHRABCG2ITGB2 | |
| SCHEMBL30360775 | 0.69 | MAOA (0.70) | MAOAMAOBTSHRABCG2ITGB2 | |
| SCHEMBL30065792 | 0.67 | — | — | |
| SCHEMBL519685 | 0.66 | TSHR (0.53) | MAOAMAOBNOS3NOS2TSHR | |
| SCHEMBL2094587 | 0.65 | MAOA (0.39) | MAOAMAOBABCG2ITGB2ICAM1 | |
| SCHEMBL31513481 | 0.65 | MAOA (0.39) | MAOAMAOBABCG2ITGB2ICAM1 | |
| SCHEMBL3074959 | 0.65 | MAOA (0.50) | MAOAMAOBABCG2ITGB2ICAM1 | |
| SCHEMBL8925 | 0.65 | MAOA (0.39) | MAOAMAOBABCG2ITGB2ICAM1 | |
| SCHEMBL33192 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 453 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774741-B1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-08 | — | — | EP | claimed |
| CN-109790164-B | Purine and 3-deazapurine analogues as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2022-01-25 | — | — | CN | claimed |
| CN-112805381-A | Compositions and methods for treating and preventing neurological disorders | 优曼尼蒂治疗公司 | 2021-05-14 | — | — | CN | claimed |
| EP-3810777-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | Yumanity Therapeutics, Inc. (US) | 2021-04-28 | — | — | EP | claimed |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | UCB Biopharma SRL (BE) | 2021-04-01 | — | — | US | claimed |
| EP-3774741-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2021-02-17 | — | — | EP | claimed |
| CN-111936472-A | Anti-malarial hexahydropyrimidine analogues | UCB生物制药有限责任公司 | 2020-11-13 | — | — | CN | claimed |
| WO-2019192992-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB BIOPHARMA SPRL (BE) | 2019-10-10 | — | — | WO | claimed |
| US-7601712-B2 | Such as (1)-2-(4-chloro-3-((2-chloro-4-(((2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-ly)methoxy)benzoyl)amino)phenyl)-2-methylpropanoic acid; prostaglandin receptor agonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-13 | — | — | US | claimed |
| US-20070123543-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | US | claimed |
| EP-0832065-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| EP-1134213-A2 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER INC. (US) | 2001-09-19 | — | — | EP | claimed |
| US-6277877-B1 | GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS | PFIZER, INC. | 2001-08-21 | — | — | US | claimed |
| US-6107329-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | PFIZER, INC. (US) | 2000-08-22 | — | — | US | claimed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | claimed |
| EP-0978279-A1 | Inhibitors of human glycogen phosphorylase | Pfizer Products Inc. (US) | 2000-02-09 | — | — | EP | claimed |
| EP-0846464-A2 | Use of glycogen phosphorylase inhibitor for reducing non-cardiac tissue damage resulting from ischemia | PFIZER INC. (US) | 1998-06-10 | — | — | EP | claimed |
| EP-0832065-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123543-A1 | Novel compounds | C1R, CHRM2, CHRM1 | MAOA 1922/4885MAOB 964/4885NOS3 1620/4885 |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | G6PD, DPYD, DHODH | MAOA 1571/4885MAOB 1471/4885NOS3 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.